COVID 19; Sons wedding; This spontaneous case was reported by a consumer and describes the occurrence of COVID-19 (COVID 19) and NO ADVERSE EVENT (Sons wedding) in a 62-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 939902, 030M28 and 041L20A) for COVID-19 vaccination.     Concurrent medical conditions included Disorder thyroid and Drug allergy (Drug name not reported). Concomitant products included LEVOTHYROXINE SODIUM (SYNTHROID) and ESTRADIOL for an unknown indication.   On 14-Jan-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Feb-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 01-Sep-2021, received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced COVID-19 (COVID 19) and NO ADVERSE EVENT (Sons wedding). The patient was treated with NIRMATRELVIR, RITONAVIR (PAXLOVID) from 17-May-2022 to 21-May-2022 for COVID-19 treatment, at an unspecified dose and frequency. At the time of the report, COVID-19 (COVID 19) and NO ADVERSE EVENT (Sons wedding) outcome was unknown.            For unspecified concomitant medication, the active drug substance reported as Synthroid, estradiol.   The patient was taking any other medications/products within 2 weeks of starting COVID-19 treatment. The patient had previously received a COVID-19 Vaccine.  No treatment medication was reported.  Company comment  This is a spontaneous case concerning a 62-year-old female patient with no relevant medical history reported and having concurrent illness of Thyroid disorder, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date after receiving a dose of mRNA-1273. Patient received the 2 primary doses with Moderna vaccine with the 2 dose given about 5 months prior to the last dose. It was reported that the patient received treatment with Paxlovid for 5 days from 17 may to 21 may 2022, for covid 19. The outcome of the event was unknown. Age of the subject, concurrent illness with Hypothyroidism are risk factors and the ongoing Covid 19 pandemia is a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per Medical judgement.; Sender's Comments: This is a spontaneous case concerning a 62-year-old female patient with no relevant medical history reported and having concurrent illness of Thyroid disorder, who experienced the non-serious, unexpected AESI event of COVID-19, which occurred on an unknown date after receiving a dose of mRNA-1273. Patient received the 2 primary doses with Moderna vaccine with the 2 dose given about 5 months prior to the last dose. It was reported that the patient received treatment with Paxlovid for 5 days from 17 may to 21 may 2022, for covid 19. The outcome of the event was unknown. Age of the subject, concurrent illness with Hypothyroidism are risk factors and the ongoing Covid 19 pandemia is a confounder. The benefit-risk relationship of mRNA-1273 vaccine is not affected by this report. Event seriousness assessed per Medical judgement.